Atomoxetine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Attention Deficit Hyperactivity Disorder
Conditions
Attention Deficit Hyperactivity Disorder
Trial Timeline
Oct 1, 2004 → Feb 1, 2006
NCT ID
NCT00191516About Atomoxetine
Atomoxetine is a phase 3 stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00191516. Target conditions include Attention Deficit Hyperactivity Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Attention Deficit Hyperactivity Disorder were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01177943 | Phase 1 | Completed |
| NCT00969618 | Phase 3 | Completed |
| NCT00760747 | Approved | Completed |
| NCT00687609 | Approved | Terminated |
| NCT00636818 | Phase 2 | Completed |
| NCT00530335 | Phase 2 | Completed |
| NCT00471354 | Approved | Completed |
| NCT00918567 | Approved | Completed |
| NCT00299234 | Approved | Terminated |
| NCT00320528 | Phase 3 | Completed |
| NCT00252278 | Approved | UNKNOWN |
| NCT00255138 | Phase 3 | Withdrawn |
| NCT00953862 | Pre-clinical | Completed |
| NCT00191633 | Approved | Completed |
| NCT00286949 | Pre-clinical | Completed |
| NCT00488163 | Approved | Completed |
| NCT00191737 | Phase 3 | Completed |
| NCT00191516 | Phase 3 | Completed |
| NCT00191880 | Phase 3 | Completed |
| NCT00191035 | Approved | Completed |
Competing Products
20 competing products in Attention Deficit Hyperactivity Disorder